Pfizer announces Phase 3 CREST trial met primary endpoint of EFS
Pfizer (PFE) announced results from the pivotal Phase 3 CREST trial of sasanlimab, an investigational anti-PD-1 monoclonal antibody, in combination with standard of care Bacillus Calmette-Guerin as induction therapy with or without maintenance in patients with BCG-naive, high-risk non-muscle invasive bladder cancer, NMIBC. The trial met its primary endpoint of event-free survival, EFS, by investigator assessment, demonstrating a clinically meaningful and statistically significant improvement with sasanlimab in combination with BCG as compared to BCG alone: Hazard Ratio of 0.68; 95% Confidence Interval, 0.49-0.94; 2-sided p=0.019; median EFS not yet reached. These findings show a 32% reduction in risk of disease-related events, including high-grade disease recurrence or progression, with the sasanlimab combination regimen as compared with SOC treatment alone. Pre-specified subgroup analyses for patients harboring higher risk disease showed consistent benefit with EFS HR of 0.63 for T1 disease, and EFS HR 0.53 for those with CIS disease.
Stay Ahead of the Market:
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Fast Company
2 hours ago
- Fast Company
China is catching up to the U.S. in pharmaceuticals, but it's not too late to turn that around
A decade ago, China had just a few hundred pharmaceutical drugs actively in development. Today, China has thousands of drugs in active development and is continually increasing investment to make even more. This transformation was not, however, a foregone conclusion: China faced incredibly high barriers to growing its pharmaceutical industry including weak research investment and a highly fragmented market of small drug development firms. However, through engineering an environment conducive to pharma innovation, China went from developing 2% of all drugs globally to 25%. Over the same period, the U.S. decreased its share from 45% to 36%, according to Evaluate's internal data. A boost in funding and regulatory changes opened the door, but access to the right talent has taken China across the threshold into a pharmaceutical golden age. Scientists from China and other parts of Asia used to come to the U.S. to work for the biggest drug companies and with the brightest minds. Now, many experts are heading East to fill China's labs, and this return began well before the current administration took office. The result? A huge increase in the quality and quantity of novel Chinese medicines in development. Licensing deals To understand the threat China poses, look to major drug companies' product portfolios. Increasingly, instead of acquiring homegrown innovations, pharma giants including Novo Nordisk, Merck & Co., AstraZeneca, and most recently Pfizer are entering into high-profile licensing deals with Chinese firms. In 2024, 31% of big pharma licensing deals involved a Chinese biotech and that number is projected to grow this year. China now offers a dizzyingly abundant source of innovative, high-quality therapies at—by pharma standards—reasonable prices. Could the U.S. pharmaceutical industry, long a shining example of innovation on the world stage, soon be eclipsed? While China's pharma industry is close to becoming the world leader, the U.S. still holds key advantages to maintain dominance. Where China Has The U.S. Beat There are three hot spots of innovation in next-generation therapies where China's lead is becoming pronounced: Bispecific Antibodies ('Bispecifics): Engineered antibodies that bind to two different targets simultaneously, offering a novel way to fight cancers. They garnered billions of dollars in sales last year and 56% of those currently in development originated in China, according to Evaluate's internal data. Antibody-Drug Conjugates ('ADCs'): These antibodies deliver a highly potent chemotherapy drug directly to cancer cells. The ADC market is projected to reach $50B by 2030 and 55% of those currently in development originated in China. Chimeric Antigen Receptor T-Cells ('CAR-Ts'): T-cells modified to recognize and kill cancer cells. The CAR-T market is expected to reach over $21B by 2030 and 51% of therapies currently in development originated in China. GLP-1s Notably, despite the increasingly crowded nature of the obesity and diabetes space, Evaluate's internal data shows 46% of GLP-1 therapies in development are from Chinese sponsors. Merck, for example, made its first move into the obesity space not by developing its own drug but by licensing a Chinese GLP-1 pill late last year. Questions remain, though, about whether Chinese players can catch Western pharma leaders which have a huge head start in the obesity space. Realistically, it's unlikely that the U.S.—or any other country—will beat China in these top three areas, though many of these Chinese drugs will be acquired by U.S. companies before they reach the market. Despite China's formidable drug development pipeline, the nation still faces outsized challenges around financing innovative and late stage trials, multiple competitors racing to patent highly similar versions of a single drug, and pricing pressure from generic versions of drugs whose patents have expired—all of which might stall China's influence. U.S. Pharma's Secret Weapons While China ramps up novel cancer treatments, the U.S. remains a powerhouse with the infrastructure, academic institutions, and regulatory systems that will ensure it continues to play a critical role in the global market. While the U.S. does not have an overwhelmingly large global share of the development of any kind of drug, it still has a significant portion of many of the largest, and most exciting types. These include: Radiopharmaceuticals: Radioactive molecules injected into the body for both targeted cancer irradiation and medical imaging. They're already a multi-billion-dollar market, and the U.S. controls 40% of those currently in development. Traditional Small Molecules: The foundation of medicine (Lipitor is an example), these drugs are still extremely widely used and the U.S. controls 37% of those currently in development. Discovery advantages Beyond dominating in these two treatment types, the U.S. has a few key advantages that will be its saving grace in the competition for biopharma dominance. The United States' ace-in-the-hole is making initial scientific discoveries. It is still the best at finding new disease processes and ways of designing drugs while China's strength is iterating on already-established successes. Take the aforementioned ADCs and CAR-Ts: these innovations were discovered in U.S. labs and China has run with tweaked versions. While China is starting to break ground on developing new biology, the U.S. still has the drug discovery edge. Secondly, U.S. investors are willing to take risks. While the Chinese state is working to create a strong environment for biotechs, private investors in China are more risk-averse than their Western counterparts. So, there is opportunity in the U.S. to support potentially high-growth areas, such as cell and gene therapy. Thirdly, don't underestimate manufacturing. Since the announcement of potential tariffs hitting the pharma industry, a number of large drug companies have announced huge investment in their U.S. manufacturing sites. Many of these were almost certainly in the cards already but more investment in the U.S. will help bolster the wider industry. The Biosecure Act also supports this effort, enforcing stricter regulations on the supply chain. Innovation insurance Finally, dealmaking is innovation insurance. U.S. big pharma is well used to sourcing innovation and drug development programs through dealmaking, so one can argue that simply extending their gaze East to draw from the new pool in China is not such a shift anyway. Many, if not most, of the next generation therapies are likely to be acquired from abroad before completing their late-stage trials in the U.S. and reaching the market. Continued international licensing will ultimately benefit the bottom lines of American companies. China's genie is out of the bottle and there is no doubt that the country's ability to develop innovative drugs will continue to thrive. As the landscape diversifies, both countries will play crucial roles in advancing pharmaceutical innovation. Both the U.S. and China hold unique advantages; now is the moment America can reinvest in theirs to come out on top.
Yahoo
2 days ago
- Yahoo
Viking Therapeutics (VKTX) Rises on Expected Developments
We recently published a list of . In this article, we are going to take a look at where Viking Therapeutics, Inc. (NASDAQ:VKTX) stands against other top-performing companies on Tuesday. Viking Therapeutics grew its share prices by 5.69 percent on Tuesday to finish at $29.14 apiece as investors loaded up positions while waiting for fresh catalysts from the series of global conferences that it is participating in this month. At present, investors are expecting updates and developments from the three-day 46th Annual Goldman Sachs Global Healthcare Conference in Florida on June 9 to 11. It is also set to participate in a one-on-one meeting at the Scotiabank Third Annual Healthcare Canadian Investor Day on June 17. In April this year, Viking Therapeutics, Inc. (NASDAQ:VKTX) soared following news that its competitor, Pfizer Inc., discontinued the development of its oral obesity medication, danuglipron, amid safety concerns. According to PFE, the decision came after a patient experienced a potential liver injury linked to the drug. A microbiologist in protective gear studying samples in a laboratory. The scrapped plans, however, spelled good news for Viking Therapeutics, Inc. (NASDAQ:VKTX), which is similarly underway with the development of an oral weight loss candidate called VK2735, with Pfizer Inc. now out of the competition. Overall, VKTX ranks 8th on our list of top-performing companies on Tuesday. While we acknowledge the potential of VKTX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 days ago
- Yahoo
Young minds dive into discovery at Pfizer School of Science Mobile Experience
MALL OF AMERICA (WLAX/WEUX) – Science came to life as curious young minds took center stage at the Pfizer School of Science Mobile Experience, a hands-on educational adventure designed to spark curiosity and inspire future scientists. Located in the North Lot of Mall of America, the immersive event welcomed kids aged 8–14 to step into the shoes of real scientists. From decoding complex clues to solving science-themed riddles, participants raced against the clock in a fully interactive escape room environment. The goal? To demonstrate that science isn't just something you read about—it's something you do. The Mobile Experience is part of Pfizer's broader School of Science initiative, an educational program aimed at igniting a passion for the life sciences in students at an early age. By combining play with problem-solving, the initiative helps demystify complex scientific concepts and makes learning genuinely fun. During these half-day field trips, students explore Pfizer's work through hands-on labs and 90-minute instructional courses covering topics like Drug Discovery, Microbiology, and Immunology. They'll also meet Pfizer professionals, gaining a real-world perspective on the impact and possibilities of a career in science. As both a mobile and in-office program, Pfizer School of Science is more than an outreach effort—it's a commitment to shaping the next generation of innovators, thinkers, and problem-solvers. With every clue cracked and every question asked, Pfizer is helping young people see that science is not just a subject, but a gateway to change the world. Whether in a mobile lab or a Manhattan office, the Pfizer School of Science is proving one thing: the future of discovery starts now. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
